Strengthen and expand collaboration to overcome intellectual property challenges and otherwise facilitate technology transfer and knowledge sharing that can promote faster paediatric formulation development, including on challenges like taste-masking.

Strengthen and expand collaboration to overcome intellectual property challenges and otherwise facilitate technology transfer and knowledge sharing that can promote faster paediatric formulation development, including on challenges like taste-masking.

Work together in a coordinated and transparent manner to ensure paediatric formulations are rapidly registered, introduced, and made widely available at an affordable cost in a maximum of high-burden countries.

Identify alternative incentives and innovative financial mechanisms for the research, development and sustained supply of paediatric formulations, including advanced purchase commitments or other interventions.

In addition to paediatric drugs and formulations in the pipeline, support the greater use of currently available WHO prequalified diagnostics and drugs in the WHO recommended regimens.

Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Provide high level political leadership and advocacy at global, country and regional levels to scale up access to paediatric HIV medications for children; production of high quality data to support implementation; and Country level support to roll out.

Continue to convene and coordinate stakeholders at a high level, including the pharmaceutical industry, FBO and civil society service providers, national governments and multilateral partners, and partners in the Start Free, Stay Free, AIDS Free Framework.

Take responsibility for monitoring implementation of the Action Plan and holding actors to account, including monthly calls of principals, tracking progress towards milestones, and regularly communicating with participants about progress on their commitments and overall implementation of the Plan.

Develop a set of milestones in 2018 to highlight progress on the Action Plan and establish opportunities for stakeholders to take on more specific commitments.

GAP-f partners develop a work plan for finalization, roll-out and increasing demand for and accelerating access to 2-3 high priority drugs planned for approval in 2018.

Continue to refine the Global Accelerator for Paediatric Formulations concept as a key component of the AIDS Free work stream, including by establishing leadership, roles and responsibilities, and a financing mechanism.

Organize a follow-up meeting focused on diagnostics for children in Q1 2018.